SCHEMBL7725873

SCHEMBL7725873

CCCCn1ccc(-c2cc(O)ccc2OC(C)C)c(NC(=O)Nc2c(C(C)C)cccc2C(C)C)c1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7725879 0.93 LPAR1 (0.46) —
SCHEMBL7735843 0.93 — —
SCHEMBL7726326 0.93 LPAR1 (0.44) —
SCHEMBL7735837 0.88 LPAR1 (0.37) —
SCHEMBL7726041 0.86 LPAR1 (0.53) —
SCHEMBL7734600 0.86 ACAT1 (0.38) —
SCHEMBL7735537 0.85 ACAT1 (0.39) —
SCHEMBL7734425 0.85 — —
SCHEMBL7735515 0.85 LPAR1 (0.52) —
SCHEMBL7734408 0.85 HRH3 (0.40) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 — — US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 — — US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 — — US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 — — EP disclosed
Send feedback